Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001104659-22-053507
Filing Date
2022-04-29
Accepted
2022-04-29 16:01:09
Documents
15
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K/A tm2213424d1_10ka.htm   iXBRL 10-K/A 268216
2 EXHIBIT 31.1 tm2213424d1_ex31-1.htm EX-31.1 3920
3 EXHIBIT 31.2 tm2213424d1_ex31-2.htm EX-31.2 3994
  Complete submission text file 0001104659-22-053507.txt   578179

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20211231.xsd EX-101.SCH 3580
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20211231_def.xml EX-101.DEF 28324
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20211231_lab.xml EX-101.LAB 38890
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20211231_pre.xml EX-101.PRE 26934
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2213424d1_10ka_htm.xml XML 7490
Mailing Address 1201 N. MARKET STREET SUITE 111 WILMINGTON DE 19801
Business Address 1201 N. MARKET STREET SUITE 111 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-38302 | Film No.: 22875027
SIC: 2834 Pharmaceutical Preparations